Impact BioMedical, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $3,629,000 for the nine months ended September 30, 2026, with common stock not listed on a national securities exchange.

Key Highlights

  • Net loss (nine months): The company reported a net loss of $3,629,000 for the nine months ended September 30, 2026, compared to $17,105,000 for the same period in 2025.
  • Total revenue (nine months): Biotech retail sales totaled $31,000 for the nine months ended September 30, 2026, up from $25,000 in the prior-year period.
  • Total assets: Total assets were $16,427,000 as of September 30, 2026, down from $17,405,000 as of December 31, 2025.
  • Accumulated deficit: The accumulated deficit stood at $53,139,000 as of September 30, 2026, compared to $49,507,000 at December 31, 2025.
  • Due to related party: The amount due to a related party increased to $1,623,000 as of September 30, 2026, from $621,000 at December 31, 2025.
  • Shares outstanding: As of November 5, 2026, there were 8,640,000 shares of common stock outstanding at $0.001 par value per share.
  • Stock-based compensation: The company recorded $1,440,000 in stock-based compensation during the nine months ended September 30, 2026, compared to $5,000 in the same period of 2025.

Impact BioMedical Reports Nine-Month Operating Results and Balance Sheet Position Through September 30, 2026

According to the filing, Impact BioMedical, Inc. reported an operating loss of $3,639,000 for the nine months ended September 30, 2026, compared to an operating loss of $3,112,000 for the same period in 2025. Total costs and expenses for the nine-month period were $3,670,000, with the largest components being sales, general and administrative compensation of $1,942,000 (inclusive of stock-based compensation), depreciation and amortization of $853,000, and professional fees of $446,000. For the three months ended September 30, 2026, the company reported a net loss of $644,000, an improvement from $1,475,000 in the prior-year quarter.

The condensed consolidated balance sheet as of September 30, 2026 showed total current assets of $102,000, down from $411,000 at December 31, 2025, with cash of $21,000. Other intangible assets, net, were $16,140,000, representing the largest component of total assets. Total current liabilities rose to $2,373,000 from $1,162,000 at year-end 2025, driven in part by the increase in amounts due to a related party. Total stockholders' equity was $13,366,000 as of September 30, 2026, compared to $15,555,000 at December 31, 2025.

The company disclosed that net cash provided by operating activities for the nine months ended September 30, 2026 was $17,000, compared to net cash used of $1,989,000 in the comparable 2025 period. The filing indicates the company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. The common stock carries a ticker of N/A and is not registered on a named exchange under Section 12(b) of the Act, according to the cover page of the filing.

What Was Disclosed

Impact BioMedical, Inc. filed a Form 10-Q for the quarterly period ended September 30, 2026, reporting a nine-month net loss of $3,629,000, total revenue of $31,000, total assets of $16,427,000, and an accumulated deficit of $53,139,000, with common stock not listed on a national exchange.